Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults
Sponsor: Gilead Sciences
A PHASE3 clinical study on HIV and HIV Infections, this trial is completed. The trial is conducted by Gilead Sciences and has accumulated 16 data snapshots since 2013. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 11 earlier versions
-
Nov 2019 — Apr 2020 [monthly]
Completed PHASE3
-
Apr 2019 — Nov 2019 [monthly]
Completed PHASE3
-
Jan 2019 — Apr 2019 [monthly]
Completed PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Oct 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Oct 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE3
-
May 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Mar 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .